Technology | 2019.03.21
Hansa Biopharma Announces Selection of NiceR Lead Candidate
LUND, Sweden, March 21, 2019 /PRNewswire/ --– Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the company has selected a lead candidate for clinical development from its NiceR program (Novel ...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]-lead-candidate-300816259.html
